HAPI Students Testify at FDA Meeting
Posted in Advocacy Announcements News News Story
On March 24, 2021, two of our HAPI students, Sophia Phillips and Kelvin Blade, testified at the FDA’s joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee on Tanezumab for Osteoarthritis.
Sophia and Kelvin, along with the guidance of HAPI co-director Dr. Adriane Fugh-Berman, presented testimony against the use of Tanezumab during the open public hearing session. See their full testimony here https://www.regulations.gov/comment/FDA-2021-N-0134-0034 (new window)